Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-30
2010-06-22
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S106000, C544S111000, C544S142000, C546S184000, C546S192000, C546S200000, C548S215000, C548S217000, C548S218000, C514S231500, C514S315000
Reexamination Certificate
active
07741343
ABSTRACT:
Compounds of the formula Iin which R1, R2, R3and R4are as defined in Claim1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behavior, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterized by an excess of circulating serotonin or by serotonergic hyperactivity.
REFERENCES:
patent: 5650427 (1997-07-01), Wikstrom et al.
patent: 6255306 (2001-07-01), Macor
patent: 6548530 (2003-04-01), Boger
patent: 7291633 (2007-11-01), Schiemann et al.
patent: 10045112 (2002-03-01), None
patent: WO 9111435 (1991-08-01), None
patent: WO 9213856 (1992-08-01), None
patent: WO 9603400 (1996-02-01), None
patent: WO 9946259 (1999-09-01), None
Boger, Dale L. et al: “CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit” Bioorg. Med. Chem. 1995, 3(6), 761-75.
Makosza, Mieczyslaw et al: “Synthesis of 1, 3, 4, 5-tetrahydropyrrolo '4, 3, 2-de! quinoli nes via the vicarious nucleophilic substitution of hydrogen” Tetrahedron (1995), 51(26), 7263-76.
John E Macor et al : “1-(2-Aminomethyl) -3-methyl-8,9-dihydropyr ane '3, 2-eindole:A Ratationalyy Restricted Phenolic Analog of the Neurotransmitter Serotonin and Agonist Selective for Serotonin (5- HT2-Type) Receptors” Journal of Medicinal Chemistry, Amercian cHEMICAL sOCIETY. Washington,US, vol. 35, No. 20, Oct. 2, 1992, pp. 3625-3632.
Boger, Dale L. et al: “CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit” Bioorg. Med. Chem. 1995, 3(6), 761-75.
Grinev et al (1981); STN International HCAPLUS database, Columbus OH, accession No. 1981:442808.
Böttcher Henning
Leibrock Joachim
Schiemann Kai
Merck Patent GmbH
Millen White Zelano & Branigan P.C.
Shameem Golam M
LandOfFree
6H-oxazolo[4,5 e]indole derivatives as nicotinic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6H-oxazolo[4,5 e]indole derivatives as nicotinic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6H-oxazolo[4,5 e]indole derivatives as nicotinic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242309